Showing 2841-2850 of 4166 results for "".
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,
- Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-phase-3-topline-results-for-netarsudil-ophthalmic-solution-002-clinical-trial-in-japan/2480342/Aerie Pharmaceuticals reported positive topline results for the company’s phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% versus ripasudil hydrochloride hydrate ophthalmic solution 0.4%. The results showed that netarsudil 0.02% once daily was s
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter
- Horizon Therapeutics Initiates Phase 4 Clinical Trial Evaluating Tepezza for the Treatment of Chronic Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-initiates-phase-4-clinical-trial-evaluating-tepezza-for-the-treatment-of-chronic-thyroid-eye-disease/2479489/Horizon Therapeutics announced that the first patient has been enrolled in a phase 4 clinical trial evaluating the efficacy and safety of Tepezza for the treatment of chronic (inactive) Thyroid Eye Disease (TED). Tepezza is the first and only medicine approved by the FDA for the treatment of TED—
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule-2/2479422/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule/2479414/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/Allegro Ophthalmics announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) an
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japanhttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-first-phase-3-clinical-trial-of-netarsudil-ophthalmic-solution-in-japan/2479300/Aerie Pharmaceuticals announced the completion of patient enrollment for its first phase 3 clinical trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02%, administered once a day in the evening, to ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Visus Therapeutics Announces Executive Leadership Appointments in Operations, Research, Clinical Operations and Intellectual Propertyhttps://modernod.com/news/visus-therapeutics-announces-executive-leadership-appointments-in-operations-research-clinical-operations-and-intellectual-property/2479290/Visus Therapeutics announced the appointment of six new senior leaders, including Tim Grinstead as Chief Operating Officer; James Burke as Vice President of Research; Patrick Hughes, PhD, as Vice President of Pharmaceutical Development; Lisa Simpson as Vice President of Clinical Operations and Co